Oxendolone

Oxendolone
Clinical data
Trade names	Prostetin, Roxenone
Other names	TSAA-291; 16β-Ethyl-19-nortestosterone; 16β-Ethylestr-4-en-17β-ol-3-one
Routes of; administration	Intramuscular injection
Drug class	Steroidal antiandrogen; Progestogen; Progestin
Pharmacokinetic data
Bioavailability	Oral: Very low (1% in dogs)
Elimination half-life	IMTooltip Intramuscular injection: 5.0–6.6 days.
Identifiers
	IUPAC name (9S,14S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one;
CAS Number	33765-68-3;
PubChem CID	36592;
ChemSpider	392001;
UNII	MN4I850D4P;
CompTox Dashboard (EPA)	DTXSID8048814 ;
Chemical and physical data
Formula	C20H30O2
Molar mass	302.458 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1CC2C3CCC4=CC(=O)CCC4C3CCC2(C1O)C;
	InChI InChI=1S/C20H30O2/c1-3-12-11-18-17-6-4-13-10-14(21)5-7-15(13)16(17)8-9-20(18,2)19(12)22/h10,12,15-19,22H,3-9,11H2,1-2H3/t12?,15?,16-,17?,18+,19+,20?/m1/s1; Key:FCKLFGKATYPJPG-LNRSQMQGSA-N;

Oxendolone, sold under the brand names Prostetin and Roxenone, is an antiandrogen and progestin medication which is used in Japan in the treatment of enlarged prostate. However, this use is controversial due to concerns about its clinical efficacy. Oxendolone is not effective by mouth and must be given by injection into muscle.

Oxendolone is an antiandrogen, and hence is an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. It is also a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. Due to its progestogenic activity, oxendolone has antigonadotropic effects. Oxendolone has no other important hormonal activity...

Oxendolone was introduced for medical use in 1981. It is used only in Japan.